We recently reported the use of human umbilical cord perivascular cells (HUCPVCs), delivered in a collagen sponge, in the healing of calvarial osteotomies in immune-suppressed rats, following their osteogenic differentiation in vitro. We compared these cells with a human bone marrow (BM) immortalized cell line, and also used conditioned medium from the latter to stimulate the osteogenic differentiation of the HUCPVCs. Our results showed that HUCPVCs provided statistically significant bony repair compared to controls, but failed to show osteogenic differentiation in vitro. On the contrary, BM cells exhibited high levels of alkaline phosphatase expression in vitro, in osteogenic assays, but when loaded onto collagen scaffolds and implanted did not produce a statistically different amount of bone from either sham or collagen-only controls. Our results demonstrated that the in vitro assays employed did not predict in vivo outcomes, and that the BM-MSC cell line employed, or CM from such cells, provided no osteogenic advantage over the use of HUCPVCs alone in vivo. Here, we discuss these findings in light of the contradictory findings of the functional phenotype of MSCs within the context of the assay employed, the age of the donor, and the tissue source of the cells. From a therapeutic perspective, it is clear that only in vivo assays should be employed as predictors of clinical performance and that cells sourced from tissue originating from younger donors may be functionally more potent than adult tissue derived MSC sources.
We recently reported the use of human umbilical cord perivascular cells (HUCPVCs) in the healing of calvarial osteotomies in rats, and compared the performance of these cells with an immortalized bone marrow mesenchymal stem cell (BM-MSC) population [1] . Our results demonstrated that our in vitro osteogenic assays did not predict in vivo outcomes, and that the BM-MSC cell line employed, provided no osteogenic advantage in vivo over the use of HUCPVCs alone. These results reflect the considerable debate that surrounds the field of mesenchymal stem cell (MSC) research. In 2006, the International Society for Cellular Therapy recommended substituting the term "stromal cell" for "stem cell", since definitive stem cell properties were rarely demonstrated in published reports [2] . In addition, the functional phenotype of MSCs derived from different tissues has been reported to differ, as does the differentiation and proliferative potential of MSCs derived from donors of different age and species.
The problem with MSC tissue source
A stark example of the variance in such reports is seen by comparing the in vitro differentiation of cell populations derived from human umbilical cord tissue. On the one hand, Bosch et al (2014) employed explant cultures of diced fragments of whole umbilical cord and compared the resultant cell population with cells derived from bone marrow and cord blood. In tri-lineage differentiation assays, cells from marrow and cord blood differentiated, while the cord tissue cells failed to differentiate in any of their assays. As a result they concluded that the cord tissue derived cells did not meet the recognized criteria of mesenchymal stromal cells [3] . These results seem to be contrary to those of Baksh et al (2007) who not only showed tri-lineage capacity of human umbilical cord perivascular cells (HUCPVCs), but concluded that "osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs [4] ." Indeed, whole journal issues have been devoted to the functional phenotype of umbilical cord tissue-derived mesenchymal cells [5] ; and Sarugaser et al (2009) have plotted the quinti-potential differentiation hierarchy of HUCPVCs, at the single cell clonal level; and thus defined a whole family of mesenchymal stem cells, based on evidence of both self-renewal and differentiation potential [6] . The variance between the differentiation potential of the matrix cells of Bosch et al (loco cit) and those of HUCPVCs may, in fact, be due to differences in the sourcing methods that could result in distinctly different cell populations. The major extracellular matrix of the human umbilical cord is the so-called Wharton's Jelly, which is a functionally specialized, though structurally simple, connective tissue comprising myofibroblasts and their secreted matrix. Like all connective tissue cells, the myofibroblast progenitors of Wharton's Jelly are considered to be mesenchymal stromal cells and Schugar et al. [7] have shown that the majority of the cells of Wharton's Jelly (77%) can be found in the perivascular regions. However, many methods to harvest cells from Wharton's Jelly remove the perivascular tissue and cells, as reviewed by Conconi et al [8] . and it is not clear if this was the case in the approach employed by Bosch et al. (loc cit). However, this could explain their conclusions that the cell phenotype they obtained was fibroblastic in nature, while Sarugaser et al. (loc cit) were able to derive true mesenchymal stem cell populations from the cord perivascular regions.
RESEARCH HIGHLIGHT

In vitro and in vivo functional phenotype differ
Another pervasive problem in assessing the functional MSC phenotype is that their mode of action in vitro and in vivo may differ significantly. The former is judged by differentiation assays developed originally for bone marrow derived cell populations, and are critically dependent upon culture medium supplements-of which fetal bovine serum is the most intangible variable. Indeed, other cell types are also known to change their functional phenotype based on assay parameters [9] ; so this is certainly not a problem unique to MSCs. An additional complication is that the in vivo mode of action of MSCs may depend more upon paracrine signaling to endogenous cells to generate a differentiated end product rather than their own, limited, differentiation. To illustrate this, and adopting a CFU-F assay as a common surrogate for an MSC [10] , if one hypothetically assumes a CFU-F frequency of 1:100, this means that 99 cells out of each 100 is not a stem cell, and thus could not be expected to differentiate according to local biological cues in a specific environment, unless already committed to that lineage due to stimulus from the source tissue. Thus, it is not surprising that a bone marrow cell population, from a normal healthy and relatively young individual, could be expected to demonstrate greater osteogenic capacity than an equivalent cell population derived from the stromal vascular fraction of adipose tissue. This is what has been reported [11, 12] .
Our recently published work has shed some further light on these important issues [1] . We chose to employ human umbilical cord perivascular tissue as a source of mesenchymal cells with a reported high frequency of mesenchymal stem cells (1:333 at harvest increasing to 1:3 at P2) [13] . We undertook both in vitro and in vivo assays on the initial assumption that we would be able to demonstrate osteogenic differentiation in both culture and following transplantation. Furthermore, based on the recently published work of Ueda's group at the Nagoya University [14] , who have shown that conditioned medium from bone marrow osteogenic cultures can stimulate a robust osteogenic response in a secondary cell population in vivo, we wished to employ conditioned medium from an osteogenic bone marrow culture to facilitate the osteogenic differentiation of the umbilical cord cells.
Our results revealed three important issues regarding our choice of both the starting cell populations and the assays employed to assess functional phenotypic outcomes.
First like Bosch et al [3] , and contrary to Baksh et al [4] , and Sarugaser et al, [6] we found that the human umbilical cord perivascular cells (HUCPVCs) showed no osteogenic differentiation in vitro, in standard osteogenic conditions [1] . We employed alkaline phosphatase, both biochemically and histochemically, and RT-PCR for osteogenic genes, as surrogates for osteogenic differentiation. These assays are commonly employed by others; although we are aware that definitive evidence of bone formation in vitro requires more stringent assays [15] . On the contrary, bone marrow derived cells stained heavily for alkaline phosphatase after both 2 and 4 weeks in culture, a finding that was confirmed by both quantitative colorimetric measurement and gene expression. Interestingly, when conditioned medium from the bone marrow culture was added to the HUCPVC cultures, colonies of alkaline phosphatase positive cells became apparent-suggesting that the addition of the conditioned medium was having a positive effect on the osteogenic differentiation of the HUCPVCs-a result seemingly in accord with the results reported by Osugi et al. [14] Nevertheless, it was interesting that gene expression for bone sialoprotein, collagen I, and Runx 2 failed to show such pronounced changes of putative osteogenic differentiation in vitro. Taken together, these results confirm the considerable variability of in vitro performance that can be seen from a putative MSC population.
Second, and contrary to our in vitro results, our in vivo assays demonstrated that HUCPVCs were the only cell population to show statistically significant bone formation within the calvarial osteotomy-this was a surprising result. However, a caveat should be introduced here since, as a result of our in vitro assays, we first cultured the HUCPVCs in osteogenic medium prior to transplantation, and did not include a control group without prior exposure to osteogenic culture conditions. Nevertheless, HUCPVCs out-performed the bone marrow cell population in this in vivo calvarial healing model, corroborating the findings of Kang et al. [16] Furthermore, it was clear from congruent immuno-labeling for human nuclear antigen and osteocalcin that some of the HUCPVCs had, indeed, differentiated in vivo, although we did not attempt to equate this with the degree of calvarial bone closure. These results are a powerful demonstration of the axiom that in vitro assays do not predict in vivo response and, given the variability of in vitro assays, as discussed above, it questions the relevance of the conclusions drawn by Bosch et al [3] based solely on in vitro assays.
MSC Age Matters
Finally, another issue that we considered important to highlight in our manuscript was the performance of our bone marrow population based on the cell source. There is no question that the vast majority of osteogenic assays reported in the literature have been undertaken on bone marrow derived cell populations. However, it is equally clear from the published literature that the number of mesenchymal stem cells in human bone marrow diminishes with age [17] . For reasons of pragmatism, we chose to purchase bone marrow cells from a commercial source. Our in vitro assays using this cell population were encouraging as they showed significant alkaline phosphatase positivity and, in addition, conditioned medium from these cells had a stimulatory effect on the HUCPVCs that had failed to show putative differentiation in vitro without this additional stimulus. However, the in vivo assays, again, demonstrated a contrary result with poor bone formation in the bone marrow group. On further analysis of this commercial source we became aware that the cell line was derived from the bone marrow of a 91-year-old female. The population was then immortalized with recombinant retroviruses by the supplier, as discussed in more detail in our paper [1] . In retrospect, it is reasonable to assume that the osteogenic capacity of the primary harvest would have been reduced compared to marrow samples from younger individuals. Thus, not only is the number of marrow resident MSCs known to decrease with age, but both age and gender affect osteogenic capacity, so it is clear that not all marrow sources will be biologically and functionally equivalent.
In summary, our findings lend some weight to two arguments. First, in vitro assays may not always reflect in vivo performance. Second, mesenchymal stem cells differentiate according to local biological cues, and thus an MSC transplanted from one connective tissue source has the capacity to differentiate into the specialized connective tissue cells of the host transplantation site.
Therapeutic Relevance
Today, MSC populations are being employed in a myriad of clinical trials for the treatment of scores of medical indications. Indeed, MSCs rank second only to the employment of immune cells in current clinical trials [18] , and umbilical cord tissue (in all its forms, but excluding umbilical cord blood) ranks the second most employed tissue source of MSCs after bone marrow -see Figure 1a . Many of these clinical trial endeavors are based on the promise, rather than the proven effectiveness, of MSCs to modulate the course of regeneration or disease-see Figure 1b . Indeed there has been, over the last decade, an emerging conventional wisdom that MSCs act, predominantly, through paracrine mechanisms in vivo rather than a demonstrable multilineage differentiation capacity. Thus, when judging the applicability of an MSC population for a particular indication an in vivo functional phenotype should be demonstrated, if at all possible, to illustrate the utility of the cell product in a particular therapeutic context. This will be of particular importance in the near future as many groups develop potency assays to predict the putative efficacy of their cell products. Clearly, relying on minimal criteria to identify an MSC population, which themselves are based on in vitro assays developed originally for only one tissue source, have little relevance to judging whether such a cell population can be called an "MSC" population or, more importantly, whether such a judgment has any clinical relevance at all.
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